Given their critical roles in gene regulation, co-activators and co-repressors are considered potential therapeutic targets in cancer treatment. Inhibitors of co-activator activity, such as small molecules targeting the HAT activity of CBP, are being explored for their anti-cancer properties. Similarly, HDAC inhibitors are being investigated to counteract the loss of co-repressor function and restore normal gene expression.
